Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 8/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | MAPK6 | Q16659 | 5/20 | 1.00 |
| ▸ | MAPKAPK3 | Q16644 | 4/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 1.00 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027845 | 0.88 | MAP2K4 (0.78) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL4084327 | 0.86 | MAP2K4 (0.76) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL4213844 | 0.85 | MAP2K4 (0.74) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5377653 | 0.84 | MAP2K4 (0.73) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL22801797 | 0.83 | MAP2K4 (1.00) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL22819421 | 0.82 | MAP2K4 (1.00) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL4029036 | 0.80 | MAP2K4 (0.67) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL22801614 | 0.76 | MAP2K4 (1.00) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL14359839 | 0.76 | MAP2K4 (0.62) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL22801717 | 0.75 | MAP2K4 (0.59) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | NORTHWESTERN UNIVERSITY (US) | 2022-06-28 | — | — | US | disclosed |
| US-20200399241-A1 | 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | US | disclosed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | MAP2K4 793/4885MAPK1 857/4885MAPK6 1322/4885 |
| US-20200399241-A1 | 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS | MAP4K3, MAPK4, MAP3K4 | MAP2K4 39/4885MAPK1 32/4885MAPK6 42/4885 |
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | MAP4K3, MAPK4, MAP3K4 | MAP2K4 39/4885MAPK1 32/4885MAPK6 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.